<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02423408</url>
  </required_header>
  <id_info>
    <org_study_id>TNX-IS-T201</org_study_id>
    <nct_id>NCT02423408</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of TNX-201 Capsules for Treatment of Single Tension-Type Headache</brief_title>
  <official_title>A Proof-of-Concept Phase 2, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-201 for the Treatment of A Single Tension-Type Headache</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tonix Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tonix Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, multicenter, double-blind, placebo-controlled, parallel-group study to
      evaluate the safety and efficacy of a single dose of TNX-201 (140 mg) for the treatment of a
      single qualifying Tension-Type-Headache (TTH).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be conducted in 4 periods (the Screening Period, the Run-In Period, the
      Double-Blind Treatment Period and the Follow-up Period) and 4 visits (the Screening Visit,
      Enrollment Visit, Randomization Visit and End-of-Study Visit).

      Screening Period- Eligible subjects who provide written informed consent to participate will
      have study assessments performed at the Screening.

      Run-In Period- The Run-In Period will last for at least 28 days. During the Run-In period,
      subjects will be assessed for frequency of headache, study compliance and to ensure they meet
      all required study criteria for randomization.

      Double-Blind Treatment Period- The Double-Blind Treatment Period (Treatment Period) will last
      up to 4 weeks or until a qualifying headache episode has occurred and been treated using the
      study drug, whichever occurs first.

      Follow-up Period- All subjects will return to the investigational site for this visit,
      regardless of whether they have treated a qualifying TTH with study medication. Subjects who
      have not treated a qualifying TTH with study drug during the Treatment Period will be asked
      to return study materials and undergo safety evaluations at the End-of-Study Visit and will
      be discharged from the study. Subjects who have treated a qualifying TTH with study drug
      during the Treatment Period will ingest a 140 mg dose of open-label TNX-201 at this visit and
      undergo urine and blood sample collection for 3 hours post-dose to characterize each
      subject's genetic metabolism and PK profile.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects Pain Free</measure>
    <time_frame>2 hours</time_frame>
    <description>Number of subjects pain free at 2 hours post-dose (Pain assessed by 4-point NRS, VAS, and binary yes/no question).
4-point NRS grades: 0=none, 1=mild, 2=moderate, 3=severe; &quot;pain-free&quot; defined as score = 0.
VAS: 0-100 scale, anchored by verbal anchors of No Pain (0) vs. Worst Imaginable Headache Pain (100). &quot;Pain-free&quot; was defined as a score &lt;= 5</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Pain Free at 15, 30, 60, 90 Minutes and 4 Hours Post-dose (Pain Will be Assessed by 4-point NRS, VAS, and Binary Yes/no Question)</measure>
    <time_frame>15, 30, 60, 90 minutes and 4 hours post-dose</time_frame>
    <description>4-point NRS grades: 0=none, 1=mild, 2=moderate, 3=severe.
VAS: 0-100 scale, No Pain vs. Worst Imaginable Headache Pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Using Rescue Medication During the 24-hour Post-dose Period</measure>
    <time_frame>24-hour post-dose period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With at Least a Two-category Improvement From Baseline at 2 Hours Post-dose in VAS Severity Category (Carvalho Responders)</measure>
    <time_frame>2 hours</time_frame>
    <description>The Carvalho Responder analysis refers to subjects with at least 2 categories of improvement in their VAS severity category (0-100 scale). VAS severity categories were defined as &quot;severe&quot; if between 52-100 inclusive, &quot;moderate&quot; between 31-51 inclusive, &quot;mild&quot; between 6-30 inclusive, and pain-free if less than 6. Therefore, a Carvalho responder was either a subject who had a VAS response classified as 'severe' at baseline and 'mild' or pain-free at the post-dose assessment time point, or a subject who had a VAS response classified as 'moderate' at baseline and pain-free at the post-dose assessment time point.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">165</enrollment>
  <condition>Tension-Type Headache</condition>
  <arm_group>
    <arm_group_label>TNX-201</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 X 35 mg capsules to be taken when qualifying tension-type headache occurs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4 X placebo capsules to be taken when qualifying tension-type headache occurs</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TNX-201</intervention_name>
    <description>TNX-201 capsule</description>
    <arm_group_label>TNX-201</arm_group_label>
    <other_name>(R)-isometheptene mucate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsule</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>TNX-201 Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Capable of reading and understanding English and able to provide written informed
             consent to participate.

          2. Male or female adults ≥ 18 and &lt; 65 years of age at the time of Visit 1.

          3. Body mass index (BMI) ≥ 18.5 and ≤ 45.0.

          4. Greater than 1 year history of episodic tension-type headache with onset prior to 50
             years of age.

          5. History of tension-type headaches that typically last ≥ 4 hours if untreated.

          6. History of 2-14 tension-type headaches per month for the last 3 months prior to Visit
             1.

          7. Diagnosis must comply with the International Headache Society (IHS) diagnostic
             criteria.

          8. No significant ECG findings at Screening

          9. If female, is either not of childbearing potential or is practicing a predefined
             medically acceptable method of birth control (hormonal methods, intrauterine device,
             double-barrier method, sexually-exclusive vasectomized male partner, same-sex
             relationship) throughout the study.

         10. Willing and able to comply with all protocol-specified requirements.

        Exclusion Criteria:

          1. Known or suspected hypersensitivity to isometheptene mucate or any excipients used in
             the formulation.

          2. Use of any excluded concomitant medications.

          3. Current use of opiate analgesics.

          4. Use of any prophylactic drug therapy for headache control within 4 weeks of screening
             (e.g., anticonvulsants, mood stabilizers, beta-blocker, antidepressants, muscle
             relaxants, botulinum toxin). Subjects taking any of these medications for an
             indication other than headache (e.g., a beta-blocker for hypertension) will require
             medical monitor's approval prior to initiation of the Run-In Period.

          5. History of medication use for acute headache on ≥ 10 days per month on average during
             the 3 months prior to Visit 1.

          6. Positive results for addictive substances (e.g., cocaine, phencyclidine (PCP),
             amphetamines, opiates) at Screening.

          7. History of migraine that exceeds a mean of four attacks per month during the preceding
             calendar year.

          8. Lifetime history of schizophrenia, schizoaffective disorder, bipolar I/II disorder,
             delusional disorder, or psychotic disorder not otherwise specified.

          9. Chronic pain disorders requiring medical treatment with opioids, chronic daily use of
             NSAIDs at the time of screening

         10. History of coronary artery disease, coronary vasospasm, aortic aneurysm, peripheral
             vascular disease or other ischemic diseases (e.g., ischemic bowel syndrome or
             Raynaud's syndrome).

         11. Inadequately controlled hypertension or persistently elevated systolic blood pressure
             or diastolic blood pressure upon repeat assessment at screening or on the day of
             randomization.

         12. Current history of two or more CAD risk factors at Screening (tobacco use, receiving
             anti-hypertensive medication for hypertension, high LDL cholesterol or low HDL
             cholesterol levels, family history of premature CAD, diabetes mellitus)

         13. History cerebral vascular accident, transient ischemic attack, seizure disorders.

         14. Other clinically significant cardiac disease.

         15. History of concurrent illness that requires hospitalization within 30 days prior to
             Visit 1.

         16. Current evidence of human immunodeficiency virus infection or clinically significant
             hepatitis B or C infection.

         17. Clinically significant laboratory abnormalities based on screening laboratory tests
             and/or medical history.

         18. Participation in another investigational trial during the 30 days prior to Visit 1 or
             during this trial. Subjects who have participated in non-interventional trials may be
             permitted to participate on a case-by-case basis after review with the Medical
             Monitor.

         19. Women who are pregnant, breast-feeding, or planning to become pregnant during this
             trial.

         20. Any other household member currently participating in a Tonix-sponsored study or
             family member or relative of investigative staff.

         21. Any condition and/or medical history that would make the subject unsuitable for study
             participation and completion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tracie Ruther, M.S</last_name>
    <role>Study Director</role>
    <affiliation>1 513 579 9911 ext 2214</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>James D. Wolfe, MD</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Avail Clinical Research LLC.</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nathan Segall, MD, CPI</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <zip>30281</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Head-Pain Neurological Institute</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gary D. Berman, MD</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Rubino, MD</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Winston-Salem, LLC.</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rapid Medical Research, Inc.</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stephan C. Sharp, MD</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duane G. Wombolt, MD</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2015</study_first_submitted>
  <study_first_submitted_qc>April 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2015</study_first_posted>
  <results_first_submitted>December 27, 2016</results_first_submitted>
  <results_first_submitted_qc>December 27, 2016</results_first_submitted_qc>
  <results_first_posted type="Actual">February 17, 2017</results_first_posted>
  <last_update_submitted>March 13, 2017</last_update_submitted>
  <last_update_submitted_qc>March 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Headache</mesh_term>
    <mesh_term>Tension-Type Headache</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>TNX-201</title>
          <description>4 X 35 mg capsules to be taken orally with a minimum of 4 ounces of water when qualifying tension-type headache occurs
TNX-201: TNX-201 capsule</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>4 X placebo capsules to be taken orally with a minimum of 4 ounces of water when qualifying tension-type headache occurs
Placebo: Placebo capsule</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="83"/>
                <participants group_id="P2" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>TNX-201</title>
          <description>4 X 35 mg capsules to be taken orally with a minimum of 4 ounces of water when qualifying tension-type headache occurs
TNX-201: TNX-201 capsule</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>4 X placebo capsules to be taken orally with a minimum of 4 ounces of water when qualifying tension-type headache occurs
Placebo: Placebo capsule</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="83"/>
            <count group_id="B2" value="82"/>
            <count group_id="B3" value="165"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="165"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="148"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Pain Free</title>
        <description>Number of subjects pain free at 2 hours post-dose (Pain assessed by 4-point NRS, VAS, and binary yes/no question).
4-point NRS grades: 0=none, 1=mild, 2=moderate, 3=severe; &quot;pain-free&quot; defined as score = 0.
VAS: 0-100 scale, anchored by verbal anchors of No Pain (0) vs. Worst Imaginable Headache Pain (100). &quot;Pain-free&quot; was defined as a score &lt;= 5</description>
        <time_frame>2 hours</time_frame>
        <population>LOCF Analysis
8 subjects in the TNX-201 group and 10 subjects in the placebo group who did not take a dose during the double-blind treatment period and/or did not report data 2-hour post-dose were excluded from analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>TNX-201</title>
            <description>4 X 35 mg capsules to be taken orally with a minimum of 4 ounces of water when qualifying tension-type headache occurs
TNX-201: TNX-201 capsule</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>4 X placebo capsules to be taken orally with a minimum of 4 ounces of water when qualifying tension-type headache occurs
Placebo: Placebo capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Pain Free</title>
          <description>Number of subjects pain free at 2 hours post-dose (Pain assessed by 4-point NRS, VAS, and binary yes/no question).
4-point NRS grades: 0=none, 1=mild, 2=moderate, 3=severe; &quot;pain-free&quot; defined as score = 0.
VAS: 0-100 scale, anchored by verbal anchors of No Pain (0) vs. Worst Imaginable Headache Pain (100). &quot;Pain-free&quot; was defined as a score &lt;= 5</description>
          <population>LOCF Analysis
8 subjects in the TNX-201 group and 10 subjects in the placebo group who did not take a dose during the double-blind treatment period and/or did not report data 2-hour post-dose were excluded from analyses.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Binary Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4-Point NRS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Pain Free at 15, 30, 60, 90 Minutes and 4 Hours Post-dose (Pain Will be Assessed by 4-point NRS, VAS, and Binary Yes/no Question)</title>
        <description>4-point NRS grades: 0=none, 1=mild, 2=moderate, 3=severe.
VAS: 0-100 scale, No Pain vs. Worst Imaginable Headache Pain</description>
        <time_frame>15, 30, 60, 90 minutes and 4 hours post-dose</time_frame>
        <population>LOCF Analysis
8 subjects in the TNX-201 group and 10 subjects in the placebo group who did not take a dose during the double-blind treatment period and/or did not report data 2-hour post-dose were excluded from analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>TNX-201</title>
            <description>4 X 35 mg capsules to be taken orally with a minimum of 4 ounces of water when qualifying tension-type headache occurs
TNX-201: TNX-201 capsule</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>4 X placebo capsules to be taken orally with a minimum of 4 ounces of water when qualifying tension-type headache occurs
Placebo: Placebo capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Pain Free at 15, 30, 60, 90 Minutes and 4 Hours Post-dose (Pain Will be Assessed by 4-point NRS, VAS, and Binary Yes/no Question)</title>
          <description>4-point NRS grades: 0=none, 1=mild, 2=moderate, 3=severe.
VAS: 0-100 scale, No Pain vs. Worst Imaginable Headache Pain</description>
          <population>LOCF Analysis
8 subjects in the TNX-201 group and 10 subjects in the placebo group who did not take a dose during the double-blind treatment period and/or did not report data 2-hour post-dose were excluded from analyses.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Binary Response : 15 Minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Binary Response : 30 Minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Binary Response : 60 Minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Binary Response : 90 Minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Binary Response : 4 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4-Point NRS : 15 Minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4-Point NRS : 30 Minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4-Point NRS : 60 Minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4-Point NRS : 90 Minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4-Point NRS : 4 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS : 15 Minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS : 30 Minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS : 60 Minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS : 90 Minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS : 4 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Using Rescue Medication During the 24-hour Post-dose Period</title>
        <time_frame>24-hour post-dose period</time_frame>
        <population>8 subjects in the TNX-201 group and 10 subjects in the placebo group who did not take a dose during the double-blind treatment period and/or did not report data 2-hour post-dose were excluded from analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>TNX-201</title>
            <description>4 X 35 mg capsules to be taken orally with a minimum of 4 ounces of water when qualifying tension-type headache occurs
TNX-201: TNX-201 capsule</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>4 X placebo capsules to be taken orally with a minimum of 4 ounces of water when qualifying tension-type headache occurs
Placebo: Placebo capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Using Rescue Medication During the 24-hour Post-dose Period</title>
          <population>8 subjects in the TNX-201 group and 10 subjects in the placebo group who did not take a dose during the double-blind treatment period and/or did not report data 2-hour post-dose were excluded from analyses.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With at Least a Two-category Improvement From Baseline at 2 Hours Post-dose in VAS Severity Category (Carvalho Responders)</title>
        <description>The Carvalho Responder analysis refers to subjects with at least 2 categories of improvement in their VAS severity category (0-100 scale). VAS severity categories were defined as &quot;severe&quot; if between 52-100 inclusive, &quot;moderate&quot; between 31-51 inclusive, &quot;mild&quot; between 6-30 inclusive, and pain-free if less than 6. Therefore, a Carvalho responder was either a subject who had a VAS response classified as ‘severe’ at baseline and ‘mild’ or pain-free at the post-dose assessment time point, or a subject who had a VAS response classified as ‘moderate’ at baseline and pain-free at the post-dose assessment time point.</description>
        <time_frame>2 hours</time_frame>
        <population>Only subjects who were categorized as &quot;severe&quot; or &quot;moderate&quot; at baseline and have data reported at 2 hours were included in this analysis. All subjects who took rescue medication at or before 2 hours were considered non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>TNX-201</title>
            <description>4 X 35 mg capsules to be taken orally with a minimum of 4 ounces of water when qualifying tension-type headache occurs
TNX-201: TNX-201 capsule</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>4 X placebo capsules to be taken orally with a minimum of 4 ounces of water when qualifying tension-type headache occurs
Placebo: Placebo capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With at Least a Two-category Improvement From Baseline at 2 Hours Post-dose in VAS Severity Category (Carvalho Responders)</title>
          <description>The Carvalho Responder analysis refers to subjects with at least 2 categories of improvement in their VAS severity category (0-100 scale). VAS severity categories were defined as &quot;severe&quot; if between 52-100 inclusive, &quot;moderate&quot; between 31-51 inclusive, &quot;mild&quot; between 6-30 inclusive, and pain-free if less than 6. Therefore, a Carvalho responder was either a subject who had a VAS response classified as ‘severe’ at baseline and ‘mild’ or pain-free at the post-dose assessment time point, or a subject who had a VAS response classified as ‘moderate’ at baseline and pain-free at the post-dose assessment time point.</description>
          <population>Only subjects who were categorized as &quot;severe&quot; or &quot;moderate&quot; at baseline and have data reported at 2 hours were included in this analysis. All subjects who took rescue medication at or before 2 hours were considered non-responders.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>5 subjects in the TNX-201 group and 9 subjects in the placebo group did not take a dose of study drug during the double-blind treatment period; therefore, these subjects were not included in the analyses.</desc>
      <group_list>
        <group group_id="E1">
          <title>TNX-201</title>
          <description>4 X 35 mg capsules to be taken orally with a minimum of 4 ounces of water when qualifying tension-type headache occurs
TNX-201: TNX-201 capsule</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>4 X placebo capsules to be taken orally with a minimum of 4 ounces of water when qualifying tension-type headache occurs
Placebo: Placebo capsule</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Feeling Hot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus Congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>An industry standard NDA in place with all study investigators.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Judith Gendreau, Senior Medical Director</name_or_title>
      <organization>Tonix Pharmaceuticals</organization>
      <phone>858-433-5574</phone>
      <email>judy.gendreau@tonixpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

